Literature DB >> 2839610

Natural and artificial immunity to varicella zoster virus.

P M Ndumbe1, J Cradock-Watson, R J Levinsky.   

Abstract

The live varicella vaccine has been recommended for use in immunocompromised subjects and in adults who are susceptible to chickenpox. However, we do not know how humoral and cell-mediated immune responses induced after vaccination differed from those obtained after natural infection. To answer this, 45 previously infected subjects (23 chickenpox, 22 vaccinated) were tested for their varicella zoster virus (VZV)-specific antibody levels and for their lymphocyte stimulation responses to VZV antigen. Antibody was measured by both an enzyme-linked immunosorbent assay (ELISA) and an immunofluorescence assay (IF), while lymphocyte stimulation was detected by tritiated thymidine incorporation. Antibody was tested in ten postchickenpox and nine vaccinated subjects. About 6 to 8 weeks after first exposure, the magnitude of the responses determined by both ELISA and IFT were much higher in the naturally infected than in the vaccinated group (P less than 0.001) with both test methods). There was no significant difference in the lymphocyte transformation responses in both groups of subjects. Thirteen postchickenpox and 13 vaccinated subjects who had been infected at least 12 months previously were also tested. Total antibody levels were again significantly higher in the naturally infected than in the vaccinated group (P less than 0.001). One vaccinated subject had VZV-specific IgA and IgM in the serum. The magnitude of the lymphocyte transformation reaction was higher in the naturally infected than in the vaccinated group (P less than 0.01). Thus, antibody responses to VZV were better in naturally infected than in vaccinated subjects. The IFT appears to be a more sensitive technique for antibody detection in the vaccinated subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839610     DOI: 10.1002/jmv.1890250207

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test.

Authors:  Andreas Sauerbrei; Anna Schäfler; Jörg Hofmann; Michael Schacke; Bernd Gruhn; Peter Wutzler
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

Review 2.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

3.  Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Authors:  Yun Hwa Kim; Ji Young Hwang; Hye Min Shim; Eunsil Lee; Songyong Park; Hosun Park
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

4.  Calibration and Evaluation of Quantitative Antibody Titers for Varicella-Zoster Virus by Use of the BioPlex 2200.

Authors:  Elizabeth McLachlan; Heidi Scholz; Shelly Bolotin; Natasha S Crowcroft; Todd F Hatchette; Colleen Jackson; Alberto Severini
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

5.  The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Haedicke; M Quinlivan; S P Steinberg; A A Gershon; K E Brown; J Breuer
Journal:  Epidemiol Infect       Date:  2016-03-28       Impact factor: 2.451

6.  Cross-Sectional Study of Varicella Zoster Virus Immunity in Healthy Korean Children Assessed by Glycoprotein Enzyme-Linked Immunosorbent Assay and Fluorescent Antibody to Membrane Antigen Test.

Authors:  Yunhwa Kim; Ji-Young Hwang; Kyung-Min Lee; Eunsil Lee; Hosun Park
Journal:  Vaccines (Basel)       Date:  2021-05-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.